RxDoctor Payments Data

Charles Gbur, MD

Cardiovascular Disease · Maumee, OHNPI 1184626483

Payments from drug & device makers

$36,073in general payments, 2019–2025

Across 529 payments — averaging $68.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$14K
  • Abbott$6K
  • Inari Medical, Inc.$5K
  • Penumbra, Inc.$3K
  • Cardiovascular Systems Inc.$1K
  • Boston Scientific$972
  • plus $6K from 39 others

What the payments were for

  • Speaking & faculty fees$8,11322%
  • Travel & lodging$11,59832%
  • Food & beverage$16,31145%
  • Education$520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,073 in reported general payments places this provider in the 85th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$149,052
Medicare patients
1,449
Services billed
3,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban354$430,401
JardianceEmpagliflozin131$174,091
XareltoRivaroxaban123$168,309
FarxigaDapagliflozin Propanediol140$150,855
EntrestoSacubitril/Valsartan37$60,844
VerquvoVericiguat31$27,277
BrilintaTicagrelor19$19,070
Repatha SureclickEvolocumab27$14,668
Repatha SyringeEvolocumab11$6,071
Amiodarone Hcl126$5,303
Ranolazine ErRanolazine43$4,775
Prasugrel Hcl22$4,694
Atorvastatin Calcium271$3,193
SotalolSotalol Hcl161$3,191
Metoprolol Succinate215$3,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$168$430,401354 claims
Boehringer IngelheimJardiance$383$174,091131 claims
AstraZenecaFarxiga, Brilinta$655$169,925159 claims
Johnson & JohnsonXarelto$501$168,309123 claims
NovartisEntresto$632$60,84437 claims
MerckVerquvo$266$27,27731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Maumee

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →